Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Expectations By $2.50 EPS

Cue Biopharma (NASDAQ:CUE – Get Free Report) issued its earnings results on Monday. The company reported ($4.74) EPS for the quarter, missing analysts’ consensus estimates of ($2.24) by ($2.50), FiscalAI reports. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. The business had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $1.03 million.

Cue Biopharma Trading Down 12.5%

NASDAQ:CUE traded down $2.02 during trading hours on Monday, hitting $14.10. The stock had a trading volume of 210,952 shares, compared to its average volume of 331,649. The company has a market cap of $102.37 million, a PE ratio of -0.52 and a beta of 2.79. The business has a 50 day simple moving average of $23.67 and a two-hundred day simple moving average of $105.57. Cue Biopharma has a 1-year low of $4.97 and a 1-year high of $45.50.

Insider Transactions at Cue Biopharma

In other news, VP Michael Vincent Meluzio sold 1,144 shares of the company’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.05, for a total value of $32,089.20. Following the completion of the transaction, the vice president directly owned 47,817 shares in the company, valued at approximately $1,341,266.85. This represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Shao-Lee Lin sold 11,087 shares of the company’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $27.55, for a total transaction of $305,446.85. Following the completion of the transaction, the chief executive officer owned 694,908 shares of the company’s stock, valued at $19,144,715.40. This trade represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 14,075 shares of company stock valued at $389,260. Corporate insiders own 14.56% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on CUE. Weiss Ratings cut shares of Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. Zacks Research upgraded Cue Biopharma to a “hold” rating in a report on Monday, September 21st. Wall Street Zen lowered Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 26th. Finally, B. Riley Financial initiated coverage on Cue Biopharma in a research note on Friday, September 18th. They set a “buy” rating and a $83.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cue Biopharma has an average rating of “Hold” and an average price target of $83.00.

Check Out Our Latest Report on Cue Biopharma

Cue Biopharma Company Profile

(Get Free Report)

Cue Biopharma, Inc. is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders. The company’s research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.

Read More

Earnings History for Cue Biopharma (NASDAQ:CUE)

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.